eMedicine Specialties > Nephrology > The Kidney in Systemic Diseases

Amyloidosis, Familial Renal: Differential Diagnoses & Workup

Author: Helen J Lachmann, MB, MA, MD, MRCP, Senior Lecturer, Department of Medicine, National Amyloidosis Centre, Royal Free and University College Medical School, UK
Coauthor(s): Philip N Hawkins, MBBS, PhD, FRCP, Clinical Director of National Amyloidosis Centre, Professor, Department of Medicine, Royal Free and University College Medical School
Contributor Information and Disclosures

Updated: Oct 29, 2009

Differential Diagnoses

Amyloidosis, AA (Inflammatory)
Amyloidosis, Immunoglobulin-Related
Amyloidosis, Transthyretin-Related

Workup

Laboratory Studies

  • No blood or urine test result is diagnostic of amyloidosis, but lab findings that exclude chronic inflammation or a monoclonal gammopathy in a patient with renal amyloid accumulation support the possibility of FRA. Lab tests also have a vital role in evaluating and monitoring amyloidotic organ function.
  • Once the creatinine clearance has fallen to less than 20%, progression to end-stage renal failure is almost inevitable, although the rate of decline often does not accord with predictions and may be remarkably slow. On the other hand, step-wise deteriorations in renal function occur quite frequently, even in the absence of any identifiable intercurrent renal insult such as dehydration, infection, or venous thrombosis.
  • Liver function test results tend to remain normal until the liver has been extensively infiltrated by amyloid, and even marked hepatomegaly may be accompanied by only a modest elevation in serum alkaline phosphatase. Liver function in those with FRA is often well preserved for decades, and elevations of serum bilirubin and transaminase levels occur at a very late stage. A bilirubin value of just twice the upper limit of normal is associated with a very poor prognosis and incipient liver failure.
  • Hematological indices and coagulation tend to be unremarkable, although a hyposplenic picture can occur. Occult GI blood loss should be considered in patients with anemia that is not secondary to renal impairment.

Imaging Studies

  • Anatomical imaging modalities (eg, plain radiography, computed tomography [CT] scan, magnetic resonance imaging [MRI], ultrasonography)
    • Typically, these yield nonspecific findings in patients with systemic amyloidosis. However, a study by Barreiros et al suggests that ultrasonography can reveal signs of amyloidosis in various organs.3 In an examination of 30 patients with systemic amyloidosis, including 19 suffering from familial amyloid polyneuropathy, the investigators found the following ultrasonographic indications of amyloidosis:
      • Heart - Myocardial thickness, pericardial and pleural effusion, and typical echorich subendocardial depositions
      • Liver and spleen - Spontaneous subcapsular hemorrhages
      • Intestine - Inhomogeneous, patchy-like depositions
      • Kidney - Somewhat unspecific results in this organ
    • Amyloidotic organs may be enlarged in the late stage of the disease, but kidney size varies and may be normal or even small at presentation.
    • Amyloid deposits are rich in calcium, and areas of calcification may develop.
    • Radionuclide tracers used for bone scintigraphy occasionally localize in amyloidotic organs.
  • SAP component scintigraphy (See images below and Images 4-6.)
    • This was introduced in 1987 and is a sensitive, specific, and noninvasive method of quantitatively imaging amyloid deposits in vivo.
    • All amyloid fibrils bind the normal plasma protein SAP by virtue of a specific calcium-dependent ligand-protein interaction.
    • In patients with amyloidosis, iodine I123 –labeled SAP localizes rapidly and specifically to the amyloid deposits.
    • The technique has a high diagnostic sensitivity and is the only method available for serial monitoring of the progression or regression of amyloid throughout the body.
    • SAP scintigraphy is eminently suitable as a screening test in patients thought to be at risk for systemic amyloid deposition, including those with known amyloidogenic mutations. However, the technique is not yet available commercially.
    • Serial SAP scans have shown that accumulation of amyloid in patients with FRA tends to be much slower compared to patients with acquired AA and AL types, and progression may not be evident, even over the course of a decade.
    • In all types of acquired and hereditary amyloidosis that have been studied, SAP scans have also shown that amyloid deposits are often cleared gradually when the supply of amyloid fibril precursor proteins can be reduced.
Progression of amyloid deposits in a patient with...

Progression of amyloid deposits in a patient with amyloidosis associated with fibrinogen A alpha-chain Glu526Val. These serial posterior, whole-body, scintigraphic images were obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a 48-year-old man with hereditary amyloidosis associated with fibrinogen A alpha-chain Glu526Val in whom asymptomatic proteinuria had been identified. Both parents were alive and well and older than age 80 years. The scan at diagnosis (left) showed modest abnormal uptake into renal amyloid deposits, which increased at follow-up 3 years later (right). The remainder of the image represents a normal distribution of tracer throughout the blood pool.

[ CLOSE WINDOW ]
Progression of amyloid deposits in a patient with...

Progression of amyloid deposits in a patient with amyloidosis associated with fibrinogen A alpha-chain Glu526Val. These serial posterior, whole-body, scintigraphic images were obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a 48-year-old man with hereditary amyloidosis associated with fibrinogen A alpha-chain Glu526Val in whom asymptomatic proteinuria had been identified. Both parents were alive and well and older than age 80 years. The scan at diagnosis (left) showed modest abnormal uptake into renal amyloid deposits, which increased at follow-up 3 years later (right). The remainder of the image represents a normal distribution of tracer throughout the blood pool.


Regression of amyloidosis associated with fibrino...

Regression of amyloidosis associated with fibrinogen A alpha-chain Glu526Val following hepatorenal transplantation. The pictures are serial anterior, whole-body, scintigraphic images obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a patient with amyloidosis associated with fibrinogen A alpha-chain Glu526Val. Prior to hepatorenal transplantation (left), heavy amyloid deposition was present in an enlarged liver and spleen. No amyloid deposits were identified in a follow-up study obtained 42 months after hepatorenal transplantation (right); only a normal distribution of tracer is present throughout the blood pool.

[ CLOSE WINDOW ]
Regression of amyloidosis associated with fibrino...

Regression of amyloidosis associated with fibrinogen A alpha-chain Glu526Val following hepatorenal transplantation. The pictures are serial anterior, whole-body, scintigraphic images obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a patient with amyloidosis associated with fibrinogen A alpha-chain Glu526Val. Prior to hepatorenal transplantation (left), heavy amyloid deposition was present in an enlarged liver and spleen. No amyloid deposits were identified in a follow-up study obtained 42 months after hepatorenal transplantation (right); only a normal distribution of tracer is present throughout the blood pool.


Regression of amyloidosis associated with apolipo...

Regression of amyloidosis associated with apolipoprotein AI Gly26Arg following hepatorenal transplantation. These serial anterior, whole-body, scintigraphic images were obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a patient with hereditary amyloidosis associated with apolipoprotein AI Gly26Arg. Prior to hepatorenal transplantation (left), heavy amyloid deposition was present in the liver, obscuring the kidneys. Two years after combined hepatorenal transplantation (right), a follow-up scan was normal, showing tracer distributed evenly throughout the background blood pool, including the transplanted organs. Splenic amyloid deposits that were evident initially in posterior scans had regressed at follow-up.

[ CLOSE WINDOW ]
Regression of amyloidosis associated with apolipo...

Regression of amyloidosis associated with apolipoprotein AI Gly26Arg following hepatorenal transplantation. These serial anterior, whole-body, scintigraphic images were obtained following intravenous injection of iodine-123 (123I)–labeled human serum amyloid P component into a patient with hereditary amyloidosis associated with apolipoprotein AI Gly26Arg. Prior to hepatorenal transplantation (left), heavy amyloid deposition was present in the liver, obscuring the kidneys. Two years after combined hepatorenal transplantation (right), a follow-up scan was normal, showing tracer distributed evenly throughout the background blood pool, including the transplanted organs. Splenic amyloid deposits that were evident initially in posterior scans had regressed at follow-up.

  • Echocardiography
    • Significant cardiac amyloid deposition is relatively unusual in patients with FRA, especially in patients with lysozyme and fibrinogen types, but confers a poor prognosis when it is present.
    • Amyloid causes diastolic dysfunction with well-preserved contractility until a very late stage.
    • Cardiac amyloidosis is best evaluated by a combination of echocardiography, ECG, and measurement of NT-pro BNP.
    • The classic findings with 2-dimensional Doppler echocardiography are concentric biventricular wall thickening, increased myocardial echodensity, thickened but pliable valves, and a restrictive filling pattern.
    • ECG findings may be normal in patients with substantial cardiac amyloidosis, but reduced voltages, pathological Q waves (ie, pseudoinfarct pattern) in the anterior chest leads, and conduction abnormalities usually signify advanced disease.

Other Tests

  • DNA analysis
    • DNA analysis is mandatory in all patients with systemic amyloidosis who cannot be confirmed absolutely to have the AA or AL type. Appreciating that the presence of a chronic inflammatory disease or a monoclonal gammopathy may be incidental is important.
    • Numerous mutations have been identified in most of the genes associated with hereditary amyloidosis, and new variants are being found regularly. Therefore, performing gene sequencing is better than using methods such as restriction fragment length polymorphism analysis, which is directed at particular known mutations.
    • The results of DNA analysis are not, by themselves, definitive proof of the presence of amyloid or the amyloid fibril type, and these findings must be interpreted in light of other clinical and histologic findings.
  • Fibril protein sequencing
    • In cases in which identifying the amyloid fibril type by more conventional means is not possible, isolation of amyloid fibrils from a sample of fresh amyloidotic tissue enables amino acid sequencing of the fibril subunit peptide.
    • This requires technical expertise and is time consuming but can be achieved using very small tissue samples. It is the most definitive method for typing amyloid deposits.

Procedures

  • The definitive diagnosis of amyloid accumulation requires histologic confirmation; however, biopsy procedures carry an increased risk of hemorrhage in patients with amyloidosis, and bleeding may be substantial and even life-threatening in 5% of patients who undergo biopsies. This is due to the increased fragility of amyloidotic blood vessels and the reduced elasticity of severely affected organs.
  • Less-invasive alternatives include fine-needle aspiration of subcutaneous fat and rectal or labial salivary gland biopsy. In experienced hands, these screening biopsies can yield positive results in as many as 80% of cases; however, in routine practice, sensitivity is only approximately 50%. Also, fat aspirates are usually not suitable for immunohistochemical typing.

Histologic Findings

Many cotton dyes, fluorescent stains such as thioflavine-T, and metachromatic stains have been used, but Congo red staining and its resultant green birefringence when viewed with high-intensity cross-polarized light has the best specificity and is the criterion standard histochemical test for amyloidosis. The stain is unstable and must be freshly prepared at least every 2 months. A section thickness of 5-10 µm and inclusion in every staining run of a positive-control tissue containing modest amounts of amyloid are critical to ensure specificity and quality control. Other problems in histologically based diagnoses include obtaining adequate tissue samples and an unavoidable element of sampling error. Biopsies cannot reveal the extent or distribution of amyloid accumulation, and failure to demonstrate amyloid in one or even several biopsies does not exclude the diagnosis.

Although many amyloid fibril proteins can be identified immunohistochemically, the demonstration of potentially amyloidogenic proteins in tissues does not, on its own, establish the presence of amyloid. Congo red staining and green birefringence are always required, and immunostaining may then enable the amyloid to be classified. Antibodies to serum amyloid A protein are commercially available and always stain AA deposits. However, in patients with AL amyloid, the deposits are stainable with standard antisera to kappa or lambda only in approximately half of all cases. This is probably because the light-chain fragment in the fibrils is usually the N-terminal variable domain, which is largely unique for each monoclonal protein.

Immunohistochemistry produces variable results in patients with FRA; the staining is typically weak in patients with fibrinogen A alpha-chain amyloid but is more reliable in patients with lysozyme and apolipoprotein AI types. Including positive tissue and absorption controls in each run is vital for optimal interpretation of the results.

The appearance of amyloid fibrils in tissues under the electron microscope is not always completely specific, and, sometimes, they cannot be identified convincingly. Although electron microscopy should be more sensitive than light microscopy, it is not sufficient by itself to confirm the diagnosis of amyloidosis.

More on Amyloidosis, Familial Renal

Overview: Amyloidosis, Familial Renal
Differential Diagnoses & Workup: Amyloidosis, Familial Renal
Treatment & Medication: Amyloidosis, Familial Renal
Follow-up: Amyloidosis, Familial Renal
Multimedia: Amyloidosis, Familial Renal
References
Further Reading
[ CLOSE WINDOW ]

References

  1. von Hutten H, Mihatsch M, Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. Aug 2009;33(8):1198-205. [Medline].

  2. Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A {alpha}-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. Jul 24 2009;[Medline].

  3. Barreiros AP, Otto G, Ignee A, et al. Sonographic signs of amyloidosis. Z Gastroenterol. Aug 2009;47(8):731-9. [Medline].

  4. Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci. Aug 24 2009;[Medline].

  5. Koike H, Morozumi S, Kawagashira Y, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. Jul 15 2009;1-7. [Medline].

  6. Amarzguioui M, Mucchiano G, Haggqvist B, et al. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun. Jan 26 1998;242(3):534-9. [Medline].

  7. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid. Jun 2005;12(2):75-87.

  8. Benson MD, Liepnieks J, Uemichi T, et al. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha- chain. Nat Genet. Mar 1993;3(3):252-5. [Medline].

  9. Booth DR, Bellotti V, Sunde M. Molecular mechanisms of amyloid fibril formation: the lysozyme model. Clin Sci. 1996;90 (Suppl 34):1P.

  10. Booth DR, Sunde M, Bellotti V, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. Feb 27 1997;385(6619):787-93. [Medline].

  11. Booth DR, Tan SY, Booth SE, et al. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM. Oct 1995;88(10):695-702. [Medline].

  12. Booth DR, Tan SY, Booth SE, et al. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest. Jun 15 1996;97(12):2714-21. [Medline].

  13. de Sousa MM, Vital C, Ostler D, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol. Jun 2000;156(6):1911-7. [Medline].

  14. Gillmore JD, Booth DR, Madhoo S, et al. Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant. Nov 1999;14(11):2639-44. [Medline].

  15. Gillmore JD, Booth DR, Rela M, et al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM. May 2000;93(5):269-75. [Medline].

  16. Hamidi Asl K, Liepnieks JJ, Nakamura M, et al. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun. Apr 13 1999;257(2):584-8. [Medline].

  17. Hamidi Asl L, Fournier V, Billerey C, et al. Fibrinogen A alpha chain mutation (Arg554 Leu) associated with hereditary renal amyloidosis in a French family. Amyloid. Dec 1998;5(4):279-84. [Medline].

  18. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K, et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol. Jan 1999;154(1):221-7. [Medline].

  19. Hamidi Asl L, Liepnieks JJ, Uemichi T, et al. Renal amyloidosis with a frame shift mutation in fibrinogen aalpha- chain gene producing a novel amyloid protein. Blood. Dec 15 1997;90(12):4799-805. [Medline].

  20. Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci (Colch). Sep 1994;87(3):289-95. [Medline].

  21. Hawkins PN, Myers MJ, Epenetos AA, et al. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med. Mar 1 1988;167(3):903-13. [Medline].

  22. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. May 1 1993;341(8853):1113-6. [Medline].

  23. Jones LA, Harding JA, Cohen AS. New USA family has apolipoprotein AI (Arg26) variant. Amyloid and Amyloidosis. 1991;385-8.

  24. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. Jun 6 2002;346(23):1786-91. [Medline].

  25. Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun. Oct 31 1988;156(2):762-8. [Medline].

  26. Obici L, Bellotti V, Mangione P, et al. The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93- residue N-terminal polypeptide. Am J Pathol. Sep 1999;155(3):695-702. [Medline].

  27. Ostertag B. Demonstration einer eigenartigen familiaren paraamyloidose. Zentralbl Aug Pathol. 1932;56:253-4.

  28. Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. Apr 8 1993;362(6420):553-7. [Medline].

  29. Persey MR, Booth DR, Booth SE. A new deletion mutation of the apolipoprotein AI gene causing hereditary amyloidosis. Clin Sci. 1996;90 (Suppl 34):33.

  30. Persey MR, Booth DR, Booth SE, et al. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int. Feb 1998;53(2):276-81. [Medline].

  31. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem. 1962;10:355-64.

  32. Rydh A, Suhr O, Hietala SO, et al. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. Jul 1998;25(7):709-13. [Medline].

  33. Sherif AM, Refaie AF, Sobh MA. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis. Aug 2003;42(2):370-5. [Medline].

  34. Soutar AK, Hawkins PN, Vigushin DM, et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A. Aug 15 1992;89(16):7389-93. [Medline].

  35. Uemichi T, Liepnieks JJ, Alexander F, Benson MD. The molecular basis of renal amyloidosis in Irish-American and Polish- Canadian kindreds. QJM. Oct 1996;89(10):745-50. [Medline].

  36. Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest. Feb 1994;93(2):731-6. [Medline].

  37. Uemichi T, Liepnieks JJ, Gertz MA, Benson MD. Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis. Amyloid. Sep 1998;5(3):188-92. [Medline].

  38. Uemichi T, Liepnieks JJ, Yamada T, et al. A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. Blood. May 15 1996;87(10):4197-203. [Medline].

  39. Zeldenrust S, Gertz M, Uemichi T. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation. Feb 27 2003;75(4):560-1. [Medline].

[ CLOSE WINDOW ]

Keywords

familial renal amyloidosis, amyloidosis, amyloid, familial amyloidosis, amyloidosis cardiac, amyloidosis disease, familial systemic amyloidosis, hereditary nonneuropathic amyloidosis, hereditary systemic amyloidosis, hereditary renal amyloidosis, Ostertag-type amyloidosis, apolipoprotein A-I amyloidosis, lysozyme amyloidosis, fibrinogen A alpha-chain amyloidosis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Helen J Lachmann, MB, MA, MD, MRCP, Senior Lecturer, Department of Medicine, National Amyloidosis Centre, Royal Free and University College Medical School, UK
Helen J Lachmann, MB, MA, MD, MRCP is a member of the following medical societies: Royal College of Physicians
Disclosure: Nothing to disclose.

Coauthor(s)

Philip N Hawkins, MBBS, PhD, FRCP, Clinical Director of National Amyloidosis Centre, Professor, Department of Medicine, Royal Free and University College Medical School
Disclosure: Nothing to disclose.

Medical Editor

Donald A Feinfeld, MD, FACP, FASN, Consulting Staff, Division of Nephrology & Hypertension, Beth Israel Medical Center
Donald A Feinfeld, MD, FACP, FASN is a member of the following medical societies: American Academy of Clinical Toxicology, American Society of Hypertension, American Society of Nephrology, and National Kidney Foundation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

George R Aronoff, MD, Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine
George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation
Disclosure: Nothing to disclose.

CME Editor

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine
Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association
Disclosure: Abbott Grant/research funds Speaking and teaching; Genzyme Honoraria Consulting; Amgen Honoraria Speaking and teaching; Ortho Biotech Honoraria Speaking and teaching

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System
Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.